Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

48.22 +0.56 (+1.16%)
Streaming Delayed Price Updated: 12:50 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
75 76 Next >
Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
From Bristol Myers Squibb
Via Business Wire
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Christopher Boerner To Take The Helm At Bristol Myers Squibb As Chair Of The Board, CEO
Via Benzinga
Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
From Bristol Myers Squibb
Via Business Wire
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Via Benzinga
Is NYSE:BMY suited for dividend investing?
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) suited for dividend investing? 
Via Chartmill
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal
Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its... 
Via Talk Markets
Why LianBio Stock Is Skyrocketing Today
Investors are loving LianBio's new deal with Bristol Myers Squibb. 
Via The Motley Fool
Pharma Giant Bristol-Myers Stock At 52-Week Low: Analyst Sees Uncertainty In Near-Term Outlook
Bristol-Myers Squibb Co (NYSE: BMY) shares are trading lower on continuous weakness following the disappointing Q3 earnings and a downward revision to the  
Via Benzinga
Bristol Myers Squibb Analysts Slash Their Forecasts Following Q3 Results
Bristol Myers Squibb & Co (NYSE: BMY) reported better-than-expected earnings for its third quarter. 
Via Benzinga
Stock Market Correction Intensifies; Google, Meta, Microsoft, Amazon Are Big Earnings Movers: Weekly Review
Microsoft, Google, Amazon and Meta led big earnings. 
Via Investor's Business Daily
Bristol Myers Squibb (BMY) Q3 2023 Earnings Call Transcript
BMY earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
US Stocks Mixed; Bristol Myers Posts Upbeat Earnings
U.S. stocks traded mixed this morning, following the release of several economic reports. Following the market opening Thursday, the Dow traded up 0.10% to 33,069.66 while the NASDAQ fell 0.24% to... 
Via Benzinga
Topics Stocks
Bristol Myers Squibb's Revlimid Sales Plunge 41%, but Opdivo and Eliquis Boost Q3, Stock Dips
Bristol Myers Squibb & Co (NYSE: BMY) said that its Q3 revenues of $10.966 billion declined 2% Y/Y, or 3% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line... 
Via Benzinga
Bristol Myers Skids 5% After Pushing Back A Key Sales Milestone By A Year
The company expects its new drugs to reach $10 billion in sales by 2026. 
Via Investor's Business Daily
Nasdaq Futures Plunge As Meta Warns Of Q4 Softness: GDP Data, Amazon Earnings On Investors' Radar Amid Market Mayhem
Stock futures are plunging after the mega-cap tech names haven't turned in the strong results that the markets had factored in. 
Via Benzinga
2 Absurdly Cheap Healthcare Stocks to Buy and Hold for Decades
You won't have to worry about paying a premium for either one of these stocks -- and they both pay a solid dividend. 
Via The Motley Fool
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
From Bristol Myers Squibb
Via Business Wire
Meta, Amazon And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Fear Continues To Grip Markets As S&P 500 Settles Below 4,200
The CNN Money Fear and Greed index showed growth easing in the overall fear level, remaining in the "Fear" zone on Wednesday. U.S. stocks closed lower on Wednesday, with the S&P 500 closing the session... 
Via Benzinga
Topics Stocks
META Up +4% On +23% Revenue Growth; IBM And NOW Also Beat
Markets sagged throughout the course of today’s trading session after starting mixed, with the Dow basking in Microsoft’s stellar previous-afternoon’s earnings report. 
Via Talk Markets
Topics Stocks
This Artificial Intelligence (AI) Stock Is Powering the Biotech Revolution: Should You Invest?
There's more to the AI boom than Microsoft and ChatGPT. 
Via The Motley Fool
Topics Artificial Intelligence
Why Is LianBio (LIAN) Stock Up 130% Today?
With LianBio inking a key exclusive licensing agreement with Bristol-Myers Squibb, LIAN stock is jumping up on the credibility implications. 
Via InvestorPlace
Why LianBio Stock Is Ripping Higher Today
LianBio (NASDAQ: LIAN) shares are trading higher Tuesday after the company announced an agreement with Bristol Myers Squibb (NYSE: BMY) to purchase LianBio's exclusive rights to develop and... 
Via Benzinga
'Never Buy A Drug Stock Just For The Yield': Jim Cramer On This Big Pharma Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended selling Petróleo Brasileiro S.A. - Petrobras (NYSE: PBR). 
Via Benzinga
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
From Bristol Myers Squibb
Via Business Wire
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises. 
Via Benzinga
Topics Stocks
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.